Bioorganic and Medicinal Chemistry Letters (2019)
Update date:2022-08-04
Topics:
Trzoss, Michael
Covel, Jonathan A.
Kapoor, Mili
Moloney, Molly K.
Soltow, Quinlyn A.
Webb, Peter J.
Shaw, Karen Joy
Fosmanogepix (APX001) is a first-in-class prodrug molecule that is currently in Phase 2 clinical trials for invasive fungal infections. The active moiety manogepix (APX001A) inhibits the novel fungal protein Gwt1. Gwt1 catalyzes an early step in the GPI anchor biosynthesis pathway. Here we describe the synthesis and evaluation of 292 new and 24 previously described analogs that were synthesized using a series of advanced intermediates to allow for rapid analoging. Several compounds demonstrated significantly (8- to 32-fold) improved antifungal activity against both Cryptococcus neoformans and C. gattii as compared to manogepix. Further in vitro characterization identified three analogs with a similar preliminary safety and in vitro profile to manogepix and superior activity against Cryptococcus spp.
View MoreGuangxi Shanyun Biochemical Science and Technology Co., Ltd
Contact:+86-0772--6828887
Address:#2 Industrial Park of Luzhai County, Liuzhou, Guangxi, China
website:http://www.lonwinchem.com
Contact:Tel: 86-21-59858395
Address:No#966,Huaxu Road,Shanghai 201702,P.R.China
Contact:+86-0311-84455288-844
Address:Mayu Industrial Park, Jinzhou, Hebei, China.
Synochem Ingredients Corp., Ltd.
Contact:+86-512-5636 2180
Address:Zhangjiagang Free Trade Zone
Tangshan Wisdom Trading Co.,Ltd
Contact:86 315 2222979
Address:No.41 BeiXinXi Road, Yangguang building 1-1102 , Tangshan, Hebei, China
Doi:10.1055/s-0036-1588422
(2017)Doi:10.1021/jo01050a549
(1962)Doi:10.1002/chem.200903158
(2010)Doi:10.1016/j.tet.2008.11.103
(2009)Doi:10.1021/acs.orglett.0c04114
(2021)Doi:10.1016/j.bmcl.2007.01.065
(2007)